Abstract
ObjectiveThis study aimed to examine the association of clinical prognostic factors with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer (NSCLC) patients.MethodsThe demographic and clinical characteristics of 94 patients with stage IV NSCLC were retrospectively reviewed, and the association between clinical factors and EGFR-TKIs efficacy was evaluated.ResultsOf the 94 stage IV NSCLC patients enrolled in this study, a 74.5% objective response rate (ORR) and 97.9% disease control rate (DCR) were observed for EGFR-TKIs treatment, and a higher ORR was seen in patients with 0 and 1 ECOG scores than those with 2 or greater scores (P = 0.049). The subjects had a median PFS of 11 months and a median OS of 31 months after EGFR-TKIs treatment. ECOG score and timing of targeted therapy were factors affecting PFS, and ECOG score, smoking status and brain metastasis were factors affecting OS. In addition, ECOG score was an independent prognostic factor for PFS in stage IV NSCLC patients, and the patients with EGFR 19del mutation had a longer PFS than those with exon 21 L855R mutation (P = 0.003), while ECOG score and brain metastasis were independent prognostic factors for OS.ConclusionsThe results of this study demonstrate that EGFR-TKI therapy results in survival benefits for EGFR-mutant advanced NSCLC patients, regardless of gender, smoking history, pathologic type, type of EGFR mutations, brain metastasis and timing of targeted therapy. ECOG score is an independent prognostic factor for PFS, and ECOG score and brain metastasis are independent prognostic factors for OS in advanced NSCLC patients.
Highlights
Lung cancer is a malignant lung tumor with the highest incidence and mortality among all cancers worldwide [1], with a 5-year survival rate of only 16.8% [2]
Of the 94 stage IV non-small-cell lung cancer (NSCLC) patients enrolled in this study, a 74.5% objective response rate (ORR) and 97.9% disease control rate (DCR) were observed for EGFRTKIs treatment, and a higher ORR was seen in patients with 0 and 1 ECOG scores than those with 2 or greater scores (P = 0.049)
Our findings demonstrate that gender, age, smoking status, pathologic type of NSCLC, type of epidermal growth factor receptor (EGFR) mutation, timing of targeted therapy, and brain metastasis do not affect the short-term efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in stage IV NSCLC patients, and oral administration of EGFR-TKIs results in clinical benefits for advanced NSCLC patients harboring EGFR mutations
Summary
Lung cancer is a malignant lung tumor with the highest incidence and mortality among all cancers worldwide [1], with a 5-year survival rate of only 16.8% [2]. Epidermal growth factor receptor (EGFR) mutation is the most common type of gene mutations detected in Asian populations with lung cancer [3, 4], and EGFR is identified as the therapeutic target of EGFR tyrosine kinase inhibitors (TKIs) [5]. First-generation EGFR-TKIs have become the standard treatment for EGFR-mutant advanced non-small-cell lung cancer (NSCLC) [6, 7]. The demographic and clinical characteristics and the timing of administration of EGFR-. Characteristics Overall Gender Age (years) Male Female ≤ 60 > 60. Median PFS (months, 95% CI) 11 (10.1–11.9). 12 (10.39–13.61) (9.26–12.74) (11.07–12.93) 10 (8.92–11.09) Smoking status No Yes
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call